(68 days)
Not Found
No
The document describes a dialyzer, a physical medical device for filtering blood, and makes no mention of software, algorithms, or AI/ML capabilities.
Yes
The device is intended for patients with renal failure when conservative therapy is inadequate, meaning it treats a medical condition.
No
Explanation: The device is a dialyzer, used for treating renal failure, not for diagnosing medical conditions. Its intended use is therapeutic rather than diagnostic.
No
The device description clearly identifies the device as a "dialyzer," which is a physical medical device used in dialysis, not a software-only product.
Based on the provided information, the Fresenius Optiflux® F250NR dialyzer is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use describes the device as being for patients with renal failure, used in a therapeutic context (dialysis). This is a treatment device, not a device used to diagnose or test samples taken from the body.
- Device Description: The description focuses on the physical construction and equivalence to other dialyzers, which are also therapeutic devices.
- Lack of IVD Indicators: The document does not mention any of the typical characteristics of an IVD, such as:
- Analyzing samples (blood, urine, tissue, etc.)
- Providing diagnostic information
- Using reagents or assays
IVDs are devices used to examine specimens from the human body to provide information for diagnosis, monitoring, or screening. Dialyzers are used to filter blood and remove waste products, which is a treatment process.
N/A
Intended Use / Indications for Use
The Optiflux F250NR dialyzers are intended for patients with acute or chronic renal failure when conservative therapy is judged to be inadequate.
Product codes (comma separated list FDA assigned to the subject device)
78KDI
Device Description
The Fresenius Optiflux® F250NR dialyzer is substantially equivalent in construction, design, materials, and intended use to the commercially available Baxter Xenium 210 and Asahi Rexeed 25S dialyzer.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 876.5860 High permeability hemodialysis system.
(a)
Identification. A high permeability hemodialysis system is a device intended for use as an artificial kidney system for the treatment of patients with renal failure, fluid overload, or toxemic conditions by performing such therapies as hemodialysis, hemofiltration, hemoconcentration, and hemodiafiltration. Using a hemodialyzer with a semipermeable membrane that is more permeable to water than the semipermeable membrane of the conventional hemodialysis system (§ 876.5820), the high permeability hemodialysis system removes toxins or excess fluid from the patient's blood using the principles of convection (via a high ultrafiltration rate) and/or diffusion (via a concentration gradient in dialysate). During treatment, blood is circulated from the patient through the hemodialyzer's blood compartment, while the dialysate solution flows countercurrent through the dialysate compartment. In this process, toxins and/or fluid are transferred across the membrane from the blood to the dialysate compartment. The hemodialysis delivery machine controls and monitors the parameters related to this processing, including the rate at which blood and dialysate are pumped through the system, and the rate at which fluid is removed from the patient. The high permeability hemodialysis system consists of the following devices:(1) The hemodialyzer consists of a semipermeable membrane with an in vitro ultrafiltration coefficient (K
uf ) greater than 8 milliliters per hour per conventional millimeter of mercury, as measured with bovine or expired human blood, and is used with either an automated ultrafiltration controller or anther method of ultrafiltration control to prevent fluid imbalance.(2) The hemodialysis delivery machine is similar to the extracorporeal blood system and dialysate delivery system of the hemodialysis system and accessories (§ 876.5820), with the addition of an ultrafiltration controller and mechanisms that monitor and/or control such parameters as fluid balance, dialysate composition, and patient treatment parameters (e.g., blood pressure, hematocrit, urea, etc.).
(3) The high permeability hemodialysis system accessories include, but are not limited to, tubing lines and various treatment related monitors (e.g., dialysate pH, blood pressure, hematocrit, and blood recirculation monitors).
(b)
Classification. Class II. The special controls for this device are FDA's:(1) “Use of International Standard ISO 10993 ‘Biological Evaluation of Medical Device—Part I: Evaluation and Testing,’ ”
(2) “Guidance for the Content of 510(k)s for Conventional and High Permeability Hemodialyzers,”
(3) “Guidance for Industry and CDRH Reviewers on the Content of Premarket Notifications for Hemodialysis Delivery Systems,”
(4) “Guidance for the Content of Premarket Notifications for Water Purification Components and Systems for Hemodialysis,” and
(5) “Guidance for Hemodialyzer Reuse Labeling.”
0
K082414 page 1 of 4
Image /page/0/Picture/1 description: The image shows a logo with a geometric design above the text "senius Medical". The geometric design consists of an inverted triangle shape, with three horizontal lines of varying thickness inside it. The text "senius Medical" is in a sans-serif font, with the first letter of each word capitalized.
OCT 2 8 2008
Confidentialresenius Medical C Fresenius Optiflux® F250NR Dialyzer 510(k) Summary
This 510(k) Summary of Safety and Effectiveness is being submitted in accordance with the requirements of SMDA 1990.
A. Submitter's Information:
| Name: | Fresenius Medical Care North America | |
|---|---|---|
| Address: | 920 Winter Street | |
| Waltham, MA 02451-1457 | ||
| Phone: | 1-781-699-4475 | |
| Fax: | (781) 699-9635 | |
| Contact Person: | Janet C. Kay RAC Regulatory Affairs Manager | |
| Date of Preparation: | January 23, 2007 |
B. Device Name:
Proprietary Name:
Common Name:
Optiflux® F250NR dialyzer
Dialyzer, High Permeability with or without Sealed Dialysate System
Product Code/Classification Panel:
78KDI/Gastroenterology-Urology
Classification:
Class II per §876.5860
53
1
X0824/4 pgx 2014
Image /page/1/Picture/1 description: The image shows a document with the word "Confidential" on the left side. To the right of "Confidential" is the text "Fresenius Medical Care". Below that is the text "Fresenius Optiflux® F250NR Dialyzer" and "510(k) Summary".
C. Predicate Devices
The Optiflux F250NR dialyzer is substantially equivalent to the Baxter Xenium 210 dialyzer and the Rexeed 25S dialyzer.
Baxter Xenium Dialyzer Model 210
- K062079 (10/19/2006) �
Asahi Kasei Rexeed Dialyzer Model 25S
- . K051187 (6/8/05)
D. Indications for Use/Intended Use:
The Optiflux F250NR dialyzers are intended for patients with acute or chronic renal failure when conservative therapy is judged to be inadequate.
E. Substantial Equivalence:
5. Is the product a device?
YES - The Fresenius Optiflux F250NR dialyzer is a device pursuant to 21 CFR §201 [321] (h).
6. Does the new device have the same intended use?
YES - The intended use for the Fresenius Optiflux F250NR dialyzer is equivalent to the Baxter Xenium dialyzer model 210 and Asahi Rexeed model 25S
Fresenius Optiflux F250NR dialyzer - Intended Use
Optiflux F250NR dialyzers are intended for patients with acute or chronic renal failure when conservative therapy is judged to be inadequate.
2
Ko 824/4 page 304
Image /page/2/Picture/1 description: The image shows the words "Confidential Fresenius Medical Care Fresenius Optiflux® F250NR Dialyzer 510(k) Summary". There is also a logo above the words "Confidential Fresenius Medical Care". The logo is a triangle pointing down with three horizontal lines inside.
Baxter Xenium dialyzer model 210 - Intended Use
Hemodialysis with Xenium dialyzers is indicated for patients with renal failure with conservative therapy is judged to be inadequate. It also may be indicated in the treatment of patients intoxicated with poisons or drugs.
Asahi Rexeed dialyzer model 25S - Intended Use
Asahi Rexeed dialyzers are intended for use in hemodialysis treatments in patients who have chronic or acute renal failure.
7. Does the device have technological characteristics that raise new types of safety or effectiveness questions?
NO - The technological characteristics of the Fresenius Optiflux F250NR dialyzer is equivalent to that of the Baxter Xenium model 210 dialyzer and Asahi Rexeed 25S and raises no new types of safety or effectiveness questions.
8. Does descriptive or performance information demonstrate equivalence?
YES - Fresenius Medical Care North America believes that the information provided in this submission clearly describes the Fresenius Optiflux F250NR and that the performance characteristics and other information supplied demonstrate that it is substantially equivalent to the Baxter Xenium dialyzer and Ashai Rexeed 25S.
F. Safety Summary
The Fresenius Optiflux® F250NR dialyzer is substantially equivalent in construction, design, materials, and intended use to the commercially available Baxter Xenium 210 and Asahi Rexeed 25S dialyzer. In addition, testing of the Fresenius Optiflux F250NR dialyzer indicates that it is safe and effective for its intended use.
3
K08244 page 4 of 4
Image /page/3/Picture/1 description: The image shows the logo for Fresenius Medical Care. Below the logo, the text "Fresenius Optiflux® F250NR Dialyzer" is written. The text "510(k) Summary" is written below the previous line.
G. General Safety and Effectiveness Concerns
The device labeling contains a package insert, which includes indications for use, cautions and warnings, as well as the general operating instructions required for proper use of the device. This information promotes safe and effective use of the Fresenius F250NR dialyzer.
Jarch ckay
Janet C. Kay RAC, Regulatory Affairs Manager
19-Aug-2008
Date
RQ
8-20-08
55 6 126
56
4
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized symbol that resembles a caduceus, a traditional symbol of medicine, but with three wavy lines instead of snakes.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
OCT 2 8 2008
Janet C. Kay, RAC Regulatory Affairs Manager Fresenius Medical Care North America 920 Winter Street WALTHAM MA 02451
Re: K082414
Trade/Device Name: Fresenius Optiflux® F250NR Dialyzer Regulation Number: 21 CFR §876.5860 Regulation Name: High permeability hemodialysis system Regulatory Class: II Product Code: KDI Dated: August 20, 2008 Received: August 21, 2008
Dear Ms. Kay:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
5
Page 2
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:
| 21 CFR 876.xxx | (Gastroenterology/Renal/Urology | 240-276-0115 |
|---|---|---|
| 21 CFR 884.xxx | (Obstetrics/Gynecology) | 240-276-0115 |
| 21 CFR 894.xxx | (Radiology) | 240-276-0120 |
| Other | 240-276-0100 |
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometrics' (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Jorgu M. Whang
Joyce M. Whang, Ph.D. Acting Director, Division of Reproductive, Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
K00-0414 page 1 of 1
Confidential
Image /page/6/Picture/2 description: The image shows the logo of Fresenius Medical Care. The logo consists of a stylized triangle pointing downwards, with three horizontal lines inside it. Below the logo, the text "Fresenius Medical C" is visible.
Fresenius Optiflux® F250NR Dialyzer
Device Name:
Fresenius Optiflux® F250NR Dialyzer
Indications for Use:
The Fresenius Optiflux® F250NR dialyzers are intended for patients with acute or chronic renal failure when conservative therapy is judged to be inadequate.
PLEASE DO NOT WRITE BELOW THIS LINE- CONTINUE ON ANOTHER PAGE IF NEEDED
(Division Sign-Off) Concurrence of CDRH, Office of Device Evaluation (ODE)
Division of Reproductive, Abdominal,
and Radiological Devices
510(k) Number. K082414
Prescription Use
(Per 21 CFR 801.109)
OR
Over-The-Counter Use
Fresenius Medical Care North America
Corporate Headquarters: 920 Winter Street Waltham, MA 02451-1457 781-699-9000
58